We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Antibody Cocktail Blocks Growth of Drug-Resistant Lung Tumors in Mouse Model

By LabMedica International staff writers
Posted on 17 Jun 2015
Print article
Image: Lung cancer cells (green) are cultured together with normal lung cells (red). The triple-antibody combination EGFR, HER2, and HER3 strongly impairs the survival of tumor cells while sparing normal cells (Photo courtesy of Weizmann Institute of Science).
Image: Lung cancer cells (green) are cultured together with normal lung cells (red). The triple-antibody combination EGFR, HER2, and HER3 strongly impairs the survival of tumor cells while sparing normal cells (Photo courtesy of Weizmann Institute of Science).
Cancer researchers developed a cocktail of three monoclonal antibodies that was able to halt drug-resistant tumor growth in a mouse xenograft lung cancer model.

Lung cancer patients with primary epidermal growth factor receptor (EGFR) mutations usually respond well to treatment with targeted kinase inhibitors, but almost always develop drug acquire resistance, often due to a second-site mutation (T790M). Clinical trials have tested the ability of a monoclonal antibody (mAb) to EGFR but failed to demonstrate any survival benefits despite the fact that the mAB should have blocked activation of the mutated receptor.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) traced the reason for this failure. By using cell lines with the T790M mutation, they discovered that prolonged exposure to mAbs against only the EGFR triggered molecular network rewiring by (i) stimulating the extracellular signal–regulated kinase (ERK) pathway; (ii) inducing the transcription of HER2 (human epidermal growth factor receptor 2) and HER3, which encode other members of the EGFR family, and the gene encoding HGF (hepatocyte growth factor), which is the ligand for the receptor tyrosine kinase MET, a molecule often expressed in metastatic cancers.

To counter the emergence of this new pathway, the investigators developed mAbs against HER2 and HER3. They reported in the June 2, 2015, online edition of the journal Science Signaling that supplementing the EGFR-specific mAb with those targeting HER2 and HER3 suppressed the compensatory feedback loops that had developed in cultured lung cancer cells. The triple mAb combination targeting all three receptors prevented the activation of ERK, accelerated the degradation of the receptors and inhibited the proliferation of tumor cells but not of normal cells. Furthermore, treatment with the antibody cocktail markedly reduced the growth of tumors in mice xenografted with cells that were resistant to combined treatment with erlotinib and the single function-blocking EGFR mAb.

"Treatment by blocking a single target can cause a feedback loop that ultimately leads to a resurgence of the cancer," said senior author Dr. Yosef Yarden, professor of molecular cell biology at the Weizmann Institute of Science. "If we can predict how the cancer cell will react when we block the growth signals it needs to continue proliferating, we can take preemptive steps to prevent this from happening."

Related Links:

Weizmann Institute of Science


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Quantitative Immunoassay Analyzer
AS050
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.